search
Back to results

Dexamethasone Blunts the Hypotensive Effect of Spinal Anesthesia in Geriatric Patients Undergoing Lower Limb Orthopedic Surgeries

Primary Purpose

Hypotension

Status
Completed
Phase
Phase 4
Locations
Egypt
Study Type
Interventional
Intervention
Dexamethasone phosphate
Placebo
Sponsored by
Ain Shams University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Hypotension

Eligibility Criteria

60 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • 110 patients aged 60 years or older
  • of the American Society of Anesthesiologists (ASA) physical status I, II or III
  • undergoing lower limb orthopedic surgeries.
  • A written informed consent was obtained from all patients to participate in the study.

Exclusion Criteria:

  • Patients with contraindication to SA (e.g.- coagulopathy,
  • thrombocytopenia,
  • allergy to local anesthetic agent)
  • and those on steroid or serotonin related medications (e.g. selective serotonin reuptake inhibitor) were excluded.

Sites / Locations

  • Ibrahim Mamdouh Esmat

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

D group, (n=55)

C group, (n=55)

Arm Description

Outcomes

Primary Outcome Measures

proportions of patients with hypotension defined as a MAP at least 25% less than the basal value at any time during the first 20 min after induction of SA before start of surgical procedure.
proportions of patients with hypotension defined as a MAP at least 25% less than the basal value at any time during the first 20 min after induction of SA before start of surgical procedure.

Secondary Outcome Measures

Full Information

First Posted
September 7, 2018
Last Updated
July 20, 2023
Sponsor
Ain Shams University
search

1. Study Identification

Unique Protocol Identification Number
NCT03664037
Brief Title
Dexamethasone Blunts the Hypotensive Effect of Spinal Anesthesia in Geriatric Patients Undergoing Lower Limb Orthopedic Surgeries
Official Title
Dexamethasone Blunts the Hypotensive Effect of Spinal Anesthesia in Geriatric Patients Undergoing Lower Limb Orthopedic Surgeries: a Double Blind, Placebo-controlled Study
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
March 1, 2018 (Actual)
Primary Completion Date
August 31, 2018 (Actual)
Study Completion Date
August 31, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ain Shams University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Based on the data that DEX increases the TPR and may decrease the expression of serotonin the investigator conducted this study to test the hypothesis that the prophylactic intravenous infusion (IVI) of DEX can attenuate the hypotensive effect of spinal anesthesia in elderly population.
Detailed Description
After approval by the institute ethics committee, this study was conducted at Ain-Shams university hospitals, from the 1st of March 2018 till the 31st of August 2018 and on 110 patients aged 60 years or older of the American Society of Anesthesiologists (ASA) physical status I, II or III. A written informed consent was obtained from all patients to participate in the study. Patients with contraindication to SA (e.g. coagulopathy, thrombocytopenia, allergy to local anesthetic agent) and those on steroid or serotonin related medications (e.g. selective serotonin reuptake inhibitor) were excluded. This study was designed to be a randomized, placebo-controlled, double-blinded parallel study. Following enrollment, patients were randomized into 2 equal groups; the D group, (n=55) each patient received 8 mg of intravenous DEX diluted in 100 ml 0.9% sodium chloride (normal saline [NS]) intravenous infusion (IVI) over 15 min 2 hours preoperatively and the C group, (n=55) each patient received 100 mL 0.9% NS IVI over 15 min (Placebo) 2 hours preoperatively. Randomization was done using computer-generated number table of random numbers in a 1:1 ratio in opaque and sealed envelope (SNOSE). The assigned treatment was written on a card and sealed in opaque envelopes consecutively numbered. These envelopes were opened just immediately before infusing the medication in the patient's room. The study drugs were prepared by the hospital pharmacy and follow-up of patients were conducted by the anesthesia residents not involved in any other part of the study. Patients were prepared by fasting (8 h for solid foods and 4 hours for clear fluids) before anesthesia and were hydrated intravenously before the procedure. Patients were hooked to a portable monitor (Non-invasive blood pressure and pulse oximetry) in their rooms from which baseline measurements (heart rate(HR), systolic(SAP), diastolic(DAP) and mean arterial blood pressure(MAP)) were recorded just before administration of the study medication. As soon as the patient arrived in the operating room pulse oximetry, electrocardiogram monitoring, and non-invasive arterial pressure measurement were started, and patients were sedated by 1mg of IV midazolam. An18-gauge intravenous cannula was inserted, and slow infusion of 0.9% sodium chloride solution was commenced to keep the vein opened and didn't exceed the volume of 200 mL during the study period (during giving anesthesia and for 20 minutes thereafter). Lumbar puncture was performed with the patient in a sitting position and the subarachnoid space was punctured at the L3-L4 or L4-L5 level using 25 gauge Quincke spinal needle under aseptic condition. After identification of the subarachnoid space3 mL of 0.5% hyperbaric bupivacaine solution (Marcaine® Spinal 0.5% Heavy; Sunny pivacaine, Manufactured by Sunny Pharmaceutical - Cairo - Egypt) were injected over 60 seconds. Immediately after completing the subarachnoid injection, patients were positioned supine on the operating table. This was followed by assessment of sensory block every 5 minutes with a cold sensation test (using alcohol swab). At the same time points, the level of motor blockade was assessed (according to the Modified Bromage Score(13) with the following categories: 0=No motor block; 1=Inability to raise extended leg; able to move knees and feet; 2=Inability to raise extended leg and move knee; able to move feet and 3=Complete block of motor limb), and the HR, SAP, DAP and the MAP were measured and recorded every 5 minutes after SA and for 4 readings thereafter. Hypotension was considered if there was 25% decrease below the baseline for MAP and was treated with IV crystalloid (Ringer solution) and incremental IV 5 mg doses of ephedrine. Bradycardia was considered if the heart rate < 50 beats/min and was treated with IV atropine (0.01mg/kg). The study end point was 20 minutes after giving the subarachnoid block during which positioning, raising tourniquet or surgical incision was not be allowed. Data collection: The hemodynamic parameter values before anesthesia and the values recorded after the blockade were used for the analysis. Analysis was done by comparing the obtained values at each study time point and by comparing the minimal values recorded within the 20 minutes following the blockade as well. When ephedrine or atropine administration was necessary, only the values obtained before this medication was used. Surgical procedure, positioning the patient or application of tourniquet was not allowed during the study period. Outcomes: The primary outcome variable in this study was proportions of patients with hypotension defined as a MAP at least 25% less than the basal value at any time during the first 20 min after induction of SA before start of surgical procedure. The secondary outcomes were: The characteristics of the motor blockade. The changes in the MAP, SAP, and DAP values in both patient groups, which were recorded before blockade and at 5-minute intervals after the block (till 20 minutes following the blockade). The changes in the heart rate (HR). The total ephedrine consumption was given to correct hypotension. The total atropine consumption was given to correct bradycardia. 3-Analysis of Data: Depending on Baig et al.,2017(14) who found that the hypotension rate in ondansetron and normal saline groups 7.5% and 28.3% respectively, and assuming the power= 0.80 and α=0.05 and by using PASS 11th release the minimal sample size for an equal size controlled clinical trial was 50 in each group. The investigator recruited 55 in each group for possible attrition(15). The collected data were coded, tabulated, and statistically analyzed using IBM SPSS statistics (Statistical Package for Social Sciences) software version 22.0, IBM Corp., Chicago, USA, 2013.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypotension

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
110 (Actual)

8. Arms, Groups, and Interventions

Arm Title
D group, (n=55)
Arm Type
Active Comparator
Arm Title
C group, (n=55)
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Dexamethasone phosphate
Intervention Description
each patient received 8 mg of intravenous DEX diluted in 100 ml 0.9% sodium chloride (normal saline [NS]) intravenous infusion (IVI) over 15 min 2 hours preoperatively
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
each patient received 100 mL 0.9% NS IVI over 15 min (Placebo) 2 hours preoperatively
Primary Outcome Measure Information:
Title
proportions of patients with hypotension defined as a MAP at least 25% less than the basal value at any time during the first 20 min after induction of SA before start of surgical procedure.
Description
proportions of patients with hypotension defined as a MAP at least 25% less than the basal value at any time during the first 20 min after induction of SA before start of surgical procedure.
Time Frame
The first 20 minutes after induction of SA before start of surgical procedure.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 110 patients aged 60 years or older of the American Society of Anesthesiologists (ASA) physical status I, II or III undergoing lower limb orthopedic surgeries. A written informed consent was obtained from all patients to participate in the study. Exclusion Criteria: Patients with contraindication to SA (e.g.- coagulopathy, thrombocytopenia, allergy to local anesthetic agent) and those on steroid or serotonin related medications (e.g. selective serotonin reuptake inhibitor) were excluded.
Facility Information:
Facility Name
Ibrahim Mamdouh Esmat
City
Heliopolis
State/Province
Cairo
ZIP/Postal Code
11361
Country
Egypt

12. IPD Sharing Statement

Citations:
PubMed Identifier
33430772
Citation
Ashoor TM, Hussien NS, Anis SG, Esmat IM. Dexamethasone blunts postspinal hypotension in geriatric patients undergoing orthopedic surgery: a double blind, placebo-controlled study. BMC Anesthesiol. 2021 Jan 11;21(1):11. doi: 10.1186/s12871-021-01232-w.
Results Reference
derived

Learn more about this trial

Dexamethasone Blunts the Hypotensive Effect of Spinal Anesthesia in Geriatric Patients Undergoing Lower Limb Orthopedic Surgeries

We'll reach out to this number within 24 hrs